Kilambi News
Friday, November 20, 2026

AbbVie strikes $2.54 billion Disco deal for bispecific cancer drugs

Life Sciences Thursday, November 19, 2026 - Updated Nov 19, 2026 07:11

AbbVie agreed on Thursday to pay Germany's Disco Pharmaceuticals $40 million upfront and up to $2.5 billion in milestones to develop AND-gated bispecific therapies for solid tumours, a total deal value of up to $2.54 billion.

Why it matters: Almost all of the money is back-ended and the work is preclinical, so the deal prices an option on Disco's two-target logic platform rather than any drug, and it extends AbbVie's run of bispecific buying after its $650 million upfront RemeGen deal in January.

Data as of Deal announced by Disco Pharmaceuticals on November 19, 2026, as reported by Reuters and BioSpace the same day; neither company disclosed how many programmes the deal covers.

AbbVie has agreed to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said on Thursday, in an early-stage push on next-generation bispecific therapies.

Disco will receive $40 million upfront and up to $2.5 billion in milestone payments to develop AND-gated bispecific therapeutics for solid tumours. The approach is designed to recognise cancer cells only when two target proteins are present at the same time, which could reduce damage to healthy tissue. Disco chief executive Mark Manfredi said his company will run the research and discovery work, and AbbVie will hold the right to exclusively license selected programmes for further development once Disco completes specified research.

The deal is at a very early stage. Disco did not disclose how many programmes could be covered or when any could enter clinical development, and AbbVie’s license option applies only after the research is done. Disco has been developing AND-gated therapies for small-cell lung and colorectal cancer and expects to select a development candidate in the second half of next year.

It is Disco’s second major pharma partnership of 2026, after a January licensing deal with Amgen worth up to $618 million. For AbbVie, it follows the $650 million upfront it paid RemeGen in January for rights outside China to a bispecific medicine targeting solid tumours, as bispecific antibodies draw increased interest across the large drugmakers, including Bristol Myers Squibb, Pfizer and Merck.

Sources

  1. AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco - Reuters - 2026-11-19
  2. AbbVie grooves with DISCO's solid tumor tech in up to $2.5B licensing deal - BioSpace - 2026-11-19